

Clive Holmes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12193193/publications.pdf>

Version: 2024-02-01

81
papers

29,207
citations

50276

46
h-index

54911

84
g-index

91
all docs

91
docs citations

91
times ranked

30918
citing authors

#	ARTICLE	IF	CITATIONS
1	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
2	Inflammation in dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2022, 168, 105698.	4.4	26
3	Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer's Disease: A Review. <i>Frontiers in Human Neuroscience</i> , 2022, 16, 866434.	2.0	25
4	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
5	Common infections and increased risk of developing dementia: compelling evidence for intervention studies. <i>The Lancet Healthy Longevity</i> , 2021, . .	4.6	1
6	The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 5-22.	2.6	52
7	The Role of Adaptive and Innate Immunity in Alzheimer's Disease. , 2021, , 213-232.		0
8	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. <i>Translational Psychiatry</i> , 2020, 10, 267.	4.8	30
9	Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1219-1226.	1.9	17
10	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. <i>PLoS ONE</i> , 2019, 14, e0218111.	2.5	23
11	Microglial motility in Alzheimer's disease and after A β 42 immunotherapy: a human post-mortem study. <i>Acta Neuropathologica Communications</i> , 2019, 7, 174.	5.2	35
12	Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. <i>Translational Psychiatry</i> , 2019, 9, 154.	4.8	69
13	Persistent neuropathological effects 14 years following amyloid- β immunization in Alzheimer's disease. <i>Brain</i> , 2019, 142, 2113-2126.	7.6	127
14	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
15	Downregulated apoptosis and autophagy after anti-A β immunotherapy in Alzheimer's disease. <i>Brain Pathology</i> , 2018, 28, 603-610.	4.1	24
16	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 62, 244.e1-244.e8.	3.1	30
17	Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 88.	5.2	52
18	Use of Flutemetamol F 18 α -Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnesic Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2018, 75, 1114.	9.0	75

#	ARTICLE	IF	CITATIONS
19	Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?. <i>Autoimmunity Reviews</i> , 2018, 17, 919-925.	5.8	40
20	Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2017, 31, 147-168.	4.0	198
21	Rare coding variants in PLCC2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
22	Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.7	48
23	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , 2017, 21, 1-192.	2.8	37
24	Shared genetic contribution to ischemic stroke and Alzheimer's disease. <i>Annals of Neurology</i> , 2016, 79, 739-747.	5.3	56
25	Targeting innate immunity for neurodegenerative disorders of the central nervous system. <i>Journal of Neurochemistry</i> , 2016, 138, 653-693.	3.9	106
26	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 46, 235.e1-235.e9.	3.1	37
27	Etanercept in Alzheimer disease. <i>Neurology</i> , 2015, 84, 2161-2168.	1.1	203
28	Effect of amyloid β ($A\beta$) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase ($GSK-3\beta$). <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 445-457.	3.2	17
29	Neuroinflammation in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2015, 14, 388-405.	10.2	4,129
30	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , The, 2015, 14, 1171-1181.	10.2	124
31	Common polygenic variation enhances risk prediction for Alzheimer's disease. <i>Brain</i> , 2015, 138, 3673-3684.	7.6	359
32	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.8	173
33	Effect of active $A\beta$ immunotherapy on neurons in human Alzheimer's disease. <i>Journal of Pathology</i> , 2015, 235, 721-730.	4.5	31
34	$A\beta$ immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. <i>Acta Neuropathologica</i> , 2014, 128, 777-789.	7.7	44
35	Microglial priming in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2014, 10, 217-224.	10.1	827
36	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. <i>Nature</i> , 2014, 505, 550-554.	27.8	425

#	ARTICLE	IF	CITATIONS
37	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
38	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
39	Inflammatory components in human Alzheimer's disease and after active amyloid- β 242 immunization. Brain, 2013, 136, 2677-2696.	7.6	234
40	Male Sex Hormones and Systemic Inflammation in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2013, 27, 153-156.	1.3	41
41	Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry, 2013, 202, 121-128.	2.8	43
42	The Role of Variation at $A\beta$ PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387.	2.6	53
43	Drug repositioning for Alzheimer's disease. Nature Reviews Drug Discovery, 2012, 11, 833-846.	46.4	239
44	Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications. CNS Neuroscience and Therapeutics, 2012, 18, 64-76.	3.9	32
45	Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. New England Journal of Medicine, 2012, 366, 893-903.	27.0	626
46	Systemic inflammation and Alzheimer's disease. Biochemical Society Transactions, 2011, 39, 898-901.	3.4	67
47	Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet, The, 2011, 378, 403-411.	13.7	444
48	A Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 587-597.	2.6	33
49	Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies. Nuclear Medicine Communications, 2011, 32, 298-302.	1.1	15
50	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
51	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 764-771.	1.7	17
52	Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry, 2011, 26, 812-817.	2.7	126
53	Reduction of aggregated Tau in neuronal processes but not in the cell bodies after $A\beta$ 242 immunisation in Alzheimer's disease. Acta Neuropathologica, 2010, 120, 13-20.	7.7	80
54	Neuropathology after active $A\beta$ 242 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathologica, 2010, 120, 369-384.	7.7	122

#	ARTICLE	IF	CITATIONS
55	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	2.5	347
56	Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, A β , and Alzheimer's Disease. PLoS ONE, 2010, 5, e8764.	2.5	48
57	Microglia in neurodegenerative disease. Nature Reviews Neurology, 2010, 6, 193-201.	10.1	1,354
58	Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimer's Research and Therapy, 2010, 2, 1.	6.2	189
59	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT. Trials, 2009, 10, 57.	1.6	44
60	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	21.4	2,697
61	Role of Infection in the Pathogenesis of Alzheimer's Disease. CNS Drugs, 2009, 23, 993-1002.	5.9	66
62	Long-term effects of A β 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, The, 2008, 372, 216-223.	13.7	1,333
63	Imaging in dementia with Lewy bodies: a review. Nuclear Medicine Communications, 2007, 28, 511-519.	1.1	32
64	Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nuclear Medicine Communications, 2007, 28, 451-456.	1.1	31
65	Systemic infections and inflammation affect chronic neurodegeneration. Nature Reviews Immunology, 2007, 7, 161-167.	22.7	887
66	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology, The, 2007, 6, 305-313.	10.2	598
67	A β 2 Species Removal After A β 42 Immunization. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1040-1048.	1.7	260
68	The Molecular Pathology of Severe Dementia. , 2006, , 33-40.		0
69	Association between Dementia and Infectious Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 91-94.	1.3	161
70	Reply to –Specificity of mechanisms for plaque removal after A β 2 immunotherapy for Alzheimer disease–. Nature Medicine, 2004, 10, 118-119.	30.7	12
71	Depression in Alzheimer's disease: The effect of serotonin receptor gene variation. American Journal of Medical Genetics Part A, 2003, 119B, 40-43.	2.4	58
72	Neuropathology of human Alzheimer disease after immunization with amyloid- β peptide: a case report. Nature Medicine, 2003, 9, 448-452.	30.7	1,423

#	ARTICLE	IF	CITATIONS
73	Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. <i>Age and Ageing</i> , 2003, 32, 200-204.	1.6	71
74	The clinical phenotype of familial and sporadic late onset Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 146-149.	2.7	14
75	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. <i>Nature Genetics</i> , 1999, 21, 71-72.	21.4	260
76	Clinical involvement in anti-dementia drug trials—why bother?. <i>International Journal of Geriatric Psychiatry</i> , 1999, 14, 258-260.	2.7	3
77	Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. <i>British Journal of Psychiatry</i> , 1999, 174, 45-50.	2.8	329
78	Previous psychiatric history as a risk factor for late-life dementia: a population-based case-control study. <i>Age and Ageing</i> , 1998, 27, 181-188.	1.6	44
79	Apolipoprotein E and Functional Illness in the Elderly. <i>International Psychogeriatrics</i> , 1998, 10, 3-6.	1.0	1
80	The Camberwell Dementia Case Register. <i>International Journal of Geriatric Psychiatry</i> , 1996, 11, 369-375.	2.7	20
81	Dementia known to mental health services: First findings of a case register for a defined elderly population. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 875-881.	2.7	10